OKYO Pharma: Chairman's Entity Buys 210K Shares
Ticker: OKYO · Form: 6-K · Filed: Oct 16, 2025 · CIK: 1849296
Sentiment: neutral
Topics: insider-transaction, share-acquisition, executive-activity
TL;DR
Chairman Cerrone's firm, Panetta Partners, just bought 210,000 OKYO shares on NASDAQ.
AI Summary
On October 16, 2025, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone, acquired 210,000 ordinary shares of the Company on NASDAQ. This acquisition was made through Panetta Partners Limited.
Why It Matters
This transaction indicates confidence from a key executive in the company's future prospects, potentially signaling positive developments or a belief in the current stock valuation.
Risk Assessment
Risk Level: low — This filing is an informational report on a share acquisition by an entity associated with the Executive Chairman, not a material event that inherently increases risk.
Key Numbers
- 210,000 — Ordinary Shares Acquired (Acquired by Panetta Partners Limited, an entity associated with the Executive Chairman.)
Key Players & Entities
- OKYO Pharma LTD (company) — Registrant
- Panetta Partners Limited (company) — Acquiring entity
- Gabriele Cerrone (person) — Executive Chairman with beneficial interest
- 210,000 (dollar_amount) — Number of ordinary shares acquired
FAQ
What was the date of the announcement regarding the share acquisition?
The announcement was made on October 16, 2025.
Which entity acquired the OKYO Pharma shares?
Panetta Partners Limited acquired the shares.
Who has a beneficial interest in Panetta Partners Limited?
Gabriele Cerrone, the Executive Chairman of OKYO Pharma LTD, has a beneficial interest.
How many ordinary shares were acquired?
A total of 210,000 ordinary shares were acquired.
On which exchange were the shares acquired?
The shares were acquired on NASDAQ.
Filing Stats: 355 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2025-10-16 08:30:31
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-25-018258.txt ( ) — 58KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: October 16, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated October 16, 2025 4